No Data
No Data
Express News | Supernus Pharmaceuticals Inc - Phase 2B Study of Spn-820 in Trd Fails Primary Endpoint
Supernus' Shares Fall 22% After Depression Study Misses Endpoint
Express News | Supernus Pharmaceuticals Inc - Spn-820 Safety Profile Consistent With Previous Trials
Express News | Supernus Announces Topline Results From Phase 2B Study in Adults With Treatment Resistant Depression
Supernus Announces Topline Results From Phase 2b Study in Adults With Treatment Resistant Depression
Supernus Pharmaceuticals to Host Conference Call and Webcast on February 25, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results